Iovance Biotherapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Iovance Biotherapeutics has a total shareholder equity of $773.5M and total debt of $1,000.0K, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are $991.1M and $217.7M respectively.
Key information
0.1%
Debt to equity ratio
US$1.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$397.49m |
| Equity | US$773.46m |
| Total liabilities | US$217.66m |
| Total assets | US$991.12m |
Recent financial health updates
No updates
Recent updates
Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Nov 11Iovance Biotherapeutics: Moving To The Next Phase
Oct 03Iovance Therapeutics: Historic Product, Tough Commercial Outlook
Sep 06Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates
Aug 11
Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Aug 11Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Jun 26Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates
Sep 27Iovance submits rolling license application to FDA for skin cancer treatment lifileucel
Aug 25Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Aug 25Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss
Aug 04Iovance: TIL Cell Therapy Set To Prove Itself
Jul 11Iovance: Onward To Approval
Apr 20Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside
Mar 25Financial Position Analysis
Short Term Liabilities: IOVA's short term assets ($498.6M) exceed its short term liabilities ($118.1M).
Long Term Liabilities: IOVA's short term assets ($498.6M) exceed its long term liabilities ($99.6M).
Debt to Equity History and Analysis
Debt Level: IOVA has more cash than its total debt.
Reducing Debt: IOVA's debt to equity ratio has increased from 0% to 0.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IOVA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IOVA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.